Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.35 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TACR3 | P29371 | 3/20 | 0.33 |
| ▸ | FNTA | P49354 | 5/20 | 0.32 |
| ▸ | FNTB | P49356 | 5/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | MARS1 | P56192 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3382819 | 0.84 | ALPI (0.42) | FNTAFNTBPGGT1BKMT2A | |
| SCHEMBL1394213 | 0.81 | SLC7A5 (0.38) | RNPEPMARS1 | |
| SCHEMBL154435 | 0.79 | FNTA (0.34) | ANPEPRNPEPDNPEPMMP2MMP9 | |
| SCHEMBL907397 | 0.78 | FNTA (0.47) | TACR3FNTAFNTBPGGT1BLTA4H | |
| SCHEMBL2213322 | 0.76 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL2213310 | 0.76 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL1128048 | 0.76 | ANPEP (0.50) | ANPEPRNPEPDNPEPMMP2MMP9 | |
| Acetic Acid SCHEMBL15201184 | 0.74 | ANPEP (0.48) | ANPEPRNPEPDNPEPMMP2MMP9 | |
| SCHEMBL83020 | 0.73 | FPR1 (0.47) | FNTAFNTBPGGT1B | |
| SCHEMBL28194148 | 0.71 | ANPEP (0.42) | ANPEPRNPEPDNPEPTACR3FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129386-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | PIK3CA, PIK3CD, PIK3R5 | ANPEP 2435/4885RNPEP 2349/4885DNPEP 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.